Patients with hepatocellular carcinoma combined with metastasis can be treated with Sindilizumab, but the specific effects need to be determined on an individual basis. The PD-1 receptor expressed by T cells binds to its ligands PD-L1 and PD-L2, which can inhibit T cell proliferation and cytokine production. PD-1 ligands are upregulated in some tumor cells, and signaling through this pathway inhibits immune surveillance of tumors by activated T cells. Sindilizumab is a human immunoglobulin G4 monoclonal antibody that binds to the PD-1 receptor, blocking the immunosuppressive response mediated by its interaction with PD-L1 and PD-L2, and enhancing the anti-tumor immune effect. Sindilizumab combined with bevacizumab is used for the first-line treatment of unresectable or metastatic hepatocellular carcinoma that has not received previous systemic treatment. The effectiveness and safety of sindilizumab combined with bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma have been investigated in China, and the results showed that the median progression-free survival of sindilizumab combined with bevacizumab was 4.6 months, and the objective remission rate was 19.1%. Patients may experience immune-related adverse reactions during the use of the drug, and need to be well monitored, in addition to hepatic insufficiency, renal insufficiency, pregnancy, children and other special groups, need to have a professional doctor to guide the use of the drug.